Relay Therapeutics, Inc.
RLAY
$3.69
$0.288.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -91.18% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -91.18% | -- | |||
| Cost of Revenue | -16.71% | 14.56% | |||
| Gross Profit | 8.07% | -2.64% | |||
| SG&A Expenses | -26.61% | -8.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.72% | 8.91% | |||
| Operating Income | 12.16% | 0.13% | |||
| Income Before Tax | 8.68% | -1.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 8.68% | -1.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 8.68% | -1.40% | |||
| EBIT | 12.16% | 0.13% | |||
| EBITDA | 12.09% | -0.02% | |||
| EPS Basic | 9.77% | -0.26% | |||
| Normalized Basic EPS | 12.72% | -0.25% | |||
| EPS Diluted | 9.77% | -0.26% | |||
| Normalized Diluted EPS | 12.72% | -0.25% | |||
| Average Basic Shares Outstanding | 1.20% | 1.13% | |||
| Average Diluted Shares Outstanding | 1.20% | 1.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||